Drugs / Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02311621 | Nov 2014 → Nov 2023 overdue | ganglioneuroblastoma, neuroblastoma | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02311621 ↗ |
| Action | Deplete | “The CAR enables the T cell to recognize and kill the neuroblastoma cell through the recognition of CD171” NCT02311621 ↗ |
| Route | Intravenous | “Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)” NCT02311621 ↗ |